{
    "nct_id": "NCT05462717",
    "official_title": "Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors",
    "inclusion_criteria": "* Subject must be â‰¥18 years of age.\n* Subject must have pathologically documented, locally advanced or metastatic KRASG12C-mutated solid tumor malignancy (not amenable to curative surgery) that has previously been treated with standard-of-care therapies for respective tumor types, is intolerant to, or is considered ineligible for standard-of-care anticancer treatments.\n* ECOG performance status 0 or 1\n* Prior treatment with a KRASG12C (OFF) inhibitor allowed for dose escalation\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Primary central nervous system (CNS) tumors\n* Active brain metastases\n* Known impairment of GI function that would alter the absorption\n* Major surgical procedures within 28 days or non-study-related minor procedures within 7 days of treatment.\n* Prior therapy with KRASG12C (ON) inhibitor\n\nOther inclusion/exclusion criteria may apply.",
    "miscellaneous_criteria": ""
}